Abstract
Introduction Preeclampsia (PE) is an important cause to maternal and perinatal morbimortality. The usage of acetylsalicylic acid (ASA) and Calcium (Ca) has been recommended to risk patients’ groups as preventive measures. Amongst the preeclampsia developing risk groups there are primiparous patients. However, we verified that this kind of intervention has been barely done in Sao Paulo and it seems not to be changed despite the consistent evidence to recommend its usage. Objectives Evaluate the ASA and Ca prescription frequency to primiparous patients. Methodology A comparative and retrospective study between two groups of primiparous patients was conducted. Firstly, all primiparous patients who have developed preeclampsia between January and May of 2016 and whose child-birth happened in Hospital Maternidade Vila Nova Cachoeirinha (HMEC) in Sao Paulo were identified through records evaluation and prenatal care portfolio. After that, a control group of primiparous patients who did not present any pathology during the gestation period was chosen and they were paired accordingly to their maternal age and gestational age at the child-birth. Results From that 23 primiparous pregnant woman with preeclampsia, 17.4% took ASA; 8.7% took Ca. Amongst the primiparous who did not develop preeclampsia, 2% took ASA; 12.2% took Ca and 2% took both medications (Table 1). There were no significant differences among the groups (p = 0.094). Conclusion Despite the consistent evidences for the usage of ASA and Ca, apparently the primary care in Sao Paulo city did not widely incorporate the recommendation of preventive measures to PE among high-risk patients. It is possible to assume that this behavior standard is similar among patients with other risk factors. Considering the strategic matter of prenatal care, that observation can be taken as a first step in order to enlarge this analysis and guide public policies to increase the usage of ASA and Ca in PE-risk patients. The authors thank the support FAPESP 2014.00213/7.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Pregnancy Hypertension: An International Journal of Women's Cardiovascular Health
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
